Intellia Therapeutics, Inc. (NTLA) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Intellia Therapeutics, Inc. (NTLA) Profile & Business Summary
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | NTLA |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.intelliatx.com |
Market Trend Overview for NTLA
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-06-25 (ET)
As of 2026-06-25, NTLA is in a strong upward move. Over the longer term, the trend remains bullish.
NTLA last closed at 16.03. The price is about 1.6 ATR above its recent average price (14.52), and the market is currently in a strong upward move. Price at 16.03 is holding above minor support near 13.88. If price continues higher, it may face minor resistance around 16.73. View Support & Resistance from Options
The trend is still positive, but signs of slowing momentum suggest growing two-sided risk.
Trend score: 95 out of 100. Overall alignment is strong. The market is currently in a strong and established uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 11.94. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-06-22, reflecting a technical shift toward positive directional alignment.
[2026-06-25] Price moved quickly and looked strong, but participation was limited.Bearish signal near resistance (0.60 ATR away). Reversal risk is higher. Pattern is less clear, so strength is reduced.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Some late-day positioning was observed, but it lacked strong overnight commitment.
The model sees a credible bullish edge, with 65.0% upside probability, strong signal alignment, and reward/risk that remains meaningfully favorable.
Up probability is 65.0%, with predictability at 51% and signal agreement at 88%. Reversal risk is 18%, while reward/risk stands at 0.29. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 11.0% above the recent estimated cost basis of 14.45, which keeps the recent cost structure in a clearly stronger position. Price is in the upper half of the main cost band (15.07 to 16.25), which is usually a healthier short-term location because price is holding the stronger side of recent trading activity. The lower down support area sits around 14.56 to 14.69. About 91% of recent positioning is in profit, which is a strong backdrop, but it also means momentum needs to stay healthy to avoid profit-taking pressure. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, this is still a strong structure, but it is also fairly extended. The key is whether momentum stays orderly without slipping back toward the 14.56 to 14.69 support zone.
Short Interest & Covering Risk for NTLA
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 49%)
Structure Analysis
NTLA Short positioning looks normal. Current days to cover is 9.2 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 6/100, DTC percentile 62%) despite a strong upward price move (20D return 19.3%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-05-29 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.